Home

 

Link to COMPETE Clinical Trial

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

Targeted Radionuclide Therapy for Cancer Treatment.

PRRT as treatment option for cancers like neuroendocrine tumors. See a practicing physician and two patients talking about their experience.

Watch the Video

ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma...

Full releases >>

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation...

Full releases >>

Houston (TX, USA) and Garching (Germany), July 26, 2018 – RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a group of specialized...

Full releases >>

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>